A Phase II, Non-Randomized Study of the Use of Desatinib (Sprycel) in Treating Patients With Polycythemia Vera (PV) BMS Protocol Number: CA180-104
Phase of Trial: Phase II
Latest Information Update: 22 Jun 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 23 May 2017 Status changed from completed to discontinued due to lack of efficacy.
- 23 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.